The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer

Background: Docetaxel is the first-line treatment for castration-resistant prostate cancer (CRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminishes its efficacy in high-dose monotherapy. YK-4-279 is a small molecule inhibitor of ETV1 tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lin, Wu, Xiaofeng, Chen, Min, Huang, Huarong, He, Yan, Wang, Huaqian, Li, Dongli, Du, Zhiyun, Zhang, Kun, Goodin, Susan, Zheng, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436478/
https://www.ncbi.nlm.nih.gov/pubmed/28553168
http://dx.doi.org/10.7150/ijms.18382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436478/
https://www.ncbi.nlm.nih.gov/pubmed/28553168
http://dx.doi.org/10.7150/ijms.18382

Ejemplares similares